Pancreatic cancer has remained one of oncology’s most difficult problems for a brutal reason:
By the time many patients are diagnosed, the disease has already spread.
Chemotherapy can slow it.
Surgery can sometimes cure early localized tumors.
Targeted drugs work for a relatively small subset of patients.
But once pancreatic adenocarcinoma becomes metastatic and progresses after initial treatment, doctors have historically had very few effective options.
That changed on August 26, 2026, when the U.S. Food and Drug Administration approved Rasonque, or daraxonrasib, a once-daily pill developed by Revolution Medicines for certain adults with metastatic pancreatic adenocarcinoma.
The approval is particularly striking because of what happened in the pivotal Phase 3 trial.
Patients receiving Rasonque had a median overall survival of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy.
That is why headlines are describing the drug as potentially doubling survival.
But the qualification matters enormously.
The result does not mean every pancreatic cancer patient will now live twice as long.
The trial involved people with metastatic pancreatic ductal adenocarcinoma who had already received treatment, and the FDA approval applies to a defined group of patients with advanced disease.
Even with that limitation, the result represents one of the most important advances in pancreatic cancer treatment in years.
What Exactly Did the FDA Approve?
Rasonque is the brand name for daraxonrasib, previously known during development as RMC-6236.
It is an oral targeted therapy taken once daily.
The FDA approved it for adults with metastatic pancreatic adenocarcinoma who either:
have received at least one previous systemic treatment, or
are not candidates for multiagent systemic therapy.
That means it is not currently approved as a universal first treatment for everyone newly diagnosed with pancreatic cancer.
For many patients, conventional combination chemotherapy remains an important initial therapy.
Rasonque creates a major new option once that first-line strategy has failed—or when an intensive combination regimen is not appropriate.
Read the FDA’s official Rasonque approval announcement
The FDA described Rasonque as a first-in-class targeted therapy for metastatic pancreatic cancer.
That description is important because the drug attacks a biological mechanism scientists spent decades trying to drug successfully.
Rasonque Targets RAS, One of Cancer’s Most Important Drivers
Cancer cells grow because biological signals tell them to grow.
One of the most important signaling families is called RAS.
RAS proteins function somewhat like molecular switches.
When operating normally, they turn growth signals on when needed and then switch them off again.
Cancer-causing mutations can effectively jam that switch into an active state.
The result is persistent signaling telling cells to divide.
That contributes to tumor growth.
Pancreatic ductal adenocarcinoma is particularly dependent on this pathway.
Around 90% or more of pancreatic ductal adenocarcinomas contain mutations involving KRAS, a member of the RAS family.
For years, that presented an incredibly frustrating situation.
Researchers knew one of the major drivers of pancreatic cancer.
They simply struggled to stop it.
KRAS Was Once Called “Undruggable”
This is part of what makes the new approval scientifically interesting beyond pancreatic cancer.
KRAS was long considered one of oncology’s hardest drug targets.
Unlike some proteins, it does not present an obvious pocket where a conventional drug molecule can easily bind.
Scientists understood that mutated RAS was driving cancer.
But knowing the culprit and being able to block it are two completely different problems.
Over the past several years, researchers finally developed therapies targeting specific RAS mutations, particularly KRAS G12C.
The limitation was that pancreatic cancer frequently carries other RAS mutations, particularly KRAS G12D and G12V.
Rasonque approaches the problem differently.
It is designed as a RAS(ON) multi-selective inhibitor, meaning it targets several active forms of RAS instead of only one narrow mutation.
That gives the drug potential relevance across a much broader group of pancreatic tumors.
It Uses an Unusual “Molecular Glue” Strategy
Daraxonrasib’s mechanism is particularly clever.
The drug interacts with a naturally occurring protein inside cells called cyclophilin A.
The resulting complex can then engage active RAS proteins and interfere with the signaling cancer cells depend on.
In simplified terms, the drug recruits another protein to help grab onto a target that was historically difficult to reach.
That is why some descriptions refer to the approach as a kind of molecular glue.
Instead of trying to force a conventional inhibitor into an awkward RAS binding site, researchers created a different molecular structure capable of trapping the active cancer-driving protein.
That design could have consequences well beyond pancreatic cancer.
RAS mutations also play major roles in lung, colorectal and other cancers.
The Phase 3 Trial Included 500 Patients
FDA approval was based heavily on the RASolute 302 Phase 3 clinical trial.
Researchers enrolled 500 adults with previously treated metastatic pancreatic ductal adenocarcinoma and randomly assigned them to receive either daraxonrasib or standard chemotherapy.
The results attracted enormous attention when they were presented at the American Society of Clinical Oncology annual meeting earlier this year.
The BMJ reported that the findings received a standing ovation at the meeting, with some audience members reportedly becoming emotional.
That reaction makes more sense when the survival numbers are considered.
Median Survival Rose From 6.7 Months to 13.2 Months
Patients receiving standard chemotherapy lived a median of approximately 6.7 months.
Patients receiving daraxonrasib lived a median of:
13.2 months.
The hazard ratio for death was approximately 0.40, corresponding to about a 60% reduction in the risk of death during the trial period relative to chemotherapy.
That is an unusually large effect for a late-line metastatic pancreatic cancer trial.
It is also important to understand exactly what “median survival” means.
It does not mean every Rasonque patient lived 13.2 months.
It means half of the patients had died by that time point and half remained alive.
Some lived less.
Some lived considerably longer.
Likewise, “double survival” refers to comparing the medians between the two study groups—not a promise that an individual patient’s remaining lifespan will literally double.
The Drug Also Delayed Cancer Progression
Overall survival was not the only measure that improved.
In the RAS G12 subgroup, median progression-free survival was approximately:
7.3 months with daraxonrasib
versus
3.5 months with chemotherapy.
Progression-free survival measures how long patients live before the cancer clearly worsens or death occurs.
In the overall population, the numbers were similarly favorable, with progression-free survival around 7.2 months for daraxonrasib versus 3.6 months for chemotherapy.
That matters because living longer is not the only goal.
Keeping cancer controlled for longer can help patients maintain function and quality of life.
Tumors Shrunk More Often Too
The trial also found a substantially higher objective response rate.
Around 33% of patients treated with daraxonrasib experienced measurable tumor shrinkage, compared with approximately 12% receiving chemotherapy, according to trial reporting.
For advanced pancreatic cancer, that difference is meaningful.
A shrinking tumor may reduce pressure on nearby tissues and potentially improve symptoms depending on where the cancer is located.
But once again, this does not mean one-third of patients were cured.
An objective response means the tumor became measurably smaller according to clinical criteria.
Metastatic pancreatic cancer can still eventually develop resistance and begin growing again.
Patients Reported Better Quality of Life
This is one of the most encouraging parts of the findings.
A cancer treatment can extend life while making that extra time extremely difficult because of side effects.
Researchers therefore also looked at patient-reported symptoms and quality of life.
Daraxonrasib significantly delayed deterioration in pain and overall health-related quality of life compared with chemotherapy.
In one analysis, median time to deterioration of pain was about 9 months with daraxonrasib compared with 3.7 months with chemotherapy among patients with RAS G12 tumors.
Reuters previously reported that some patients improved enough to resume activities they had stopped because of their illness.
That can be enormously important in advanced cancer.
More months matter.
But how those months feel matters too.
It Was Better Tolerated Than Chemotherapy in the Trial
Rasonque is not side-effect free.
But serious treatment-related adverse events were less common than with standard chemotherapy in the Phase 3 study.
Trial reporting showed Grade 3 or higher treatment-related side effects in approximately 43.6% of daraxonrasib patients, compared with about 57.5% in the chemotherapy group.
Treatment discontinuation because of adverse events was also reported less frequently in the daraxonrasib group.
That matters because pancreatic cancer patients receiving second-line treatment may already be physically weakened from both the disease and previous chemotherapy.
A treatment that can prolong survival while causing fewer severe toxicities represents a particularly valuable combination.
Rasonque Still Has Significant Side Effects
“Better tolerated than chemotherapy” should not be interpreted as “easy to take.”
The FDA lists common adverse effects including:
rash,
diarrhea,
stomatitis or inflammation inside the mouth,
nausea,
fatigue,
vomiting,
abdominal pain,
edema,
decreased appetite,
and hemorrhage.
Patients require medical supervision.
Cancer drugs can interact with other medications and can produce complications that require dose changes, supportive treatment or discontinuation.
Someone reading about Rasonque should therefore not treat it like an ordinary prescription tablet.
It is a powerful oncology treatment targeting a fundamental cancer-signaling pathway.
Why Is Pancreatic Cancer So Difficult to Treat?
The approval matters because pancreatic cancer has resisted major therapeutic progress for decades.
Several factors work against doctors.
It Is Often Found Late
Early pancreatic tumors frequently produce few obvious symptoms.
The pancreas sits deep inside the abdomen, meaning a small tumor cannot easily be felt during a routine examination.
By the time symptoms such as jaundice, abdominal pain, unexplained weight loss or appetite changes become obvious, the disease may already have spread.
The National Cancer Institute notes that there is currently no established population-wide screening method capable of reliably finding pancreatic cancer early in ordinary-risk people.
National Cancer Institute pancreatic cancer information
That late diagnosis eliminates surgery as a curative option for many patients.
Surgery Only Helps a Minority of Patients
Surgery offers the strongest possibility of long-term cure when the cancer remains localized and can be completely removed.
Unfortunately, fewer than about 20% of cases are localized enough for curative surgery to be considered, according to NCI treatment guidance.
Once pancreatic cancer has spread to distant organs, surgery generally cannot remove all disease.
Treatment becomes systemic.
Chemotherapy—and now certain targeted therapies—must reach cancer cells throughout the body.
That is the population for which Rasonque becomes particularly important.
Pancreatic Tumors Have a Difficult Microenvironment
Pancreatic tumors are also biologically unusual.
They often develop dense fibrous tissue surrounding the cancer cells.
This tumor microenvironment can make it more difficult for therapies to penetrate effectively.
Pancreatic cancers can also evolve quickly and develop resistance to treatment.
Together, those characteristics help explain why drugs that work dramatically in some other cancers may produce only modest benefits in pancreatic adenocarcinoma.
Directly targeting one of the cancer’s central growth pathways offers a fundamentally different strategy.
Most Pancreatic Cancer Is Pancreatic Adenocarcinoma
Pancreatic cancer is not one single disease.
The FDA notes that approximately 90% to 95% of the roughly 67,000 new pancreatic cancer cases expected annually in the United States are pancreatic adenocarcinoma.
This is the cancer type Rasonque targets.
Other pancreatic tumors—including neuroendocrine tumors—have different biology and can require very different treatments.
So someone diagnosed with “pancreatic cancer” should not assume Rasonque automatically applies.
The exact pathology matters.
The Overall Five-Year Survival Rate Remains Extremely Low
Pancreatic cancer continues to have one of the poorest survival rates among common cancers.
Recent reporting puts the U.S. five-year survival rate at around 13% overall.
But that number combines different stages.
Early-stage disease that can be surgically removed has a much better outlook.
Metastatic disease has a far worse one.
This is why gaining another six or seven months of median survival in previously treated metastatic disease is clinically significant.
In some cancers, adding several months might look incremental.
In late-stage pancreatic cancer, nearly doubling median survival represents an entirely different scale of benefit.
Why Didn’t Doctors Target KRAS Years Ago?
Researchers certainly tried.
KRAS mutations were identified as important cancer drivers decades ago.
The obstacle was chemistry.
RAS proteins bind their natural molecules extremely tightly and lack many of the structural pockets drug developers normally exploit.
For years, researchers repeatedly failed to create drugs capable of shutting the pathway down safely and effectively.
That gave KRAS its “undruggable” reputation.
The first major cracks came with drugs selectively targeting KRAS G12C.
Those successes proved RAS could be attacked pharmacologically.
Daraxonrasib pushes the idea further by targeting multiple active RAS forms.
Learn about Revolution Medicines’ RAS-targeting research
That makes Rasonque’s approval important not only because of pancreatic cancer.
It validates a broader technological strategy.
Could This Work in Other Cancers?
Potentially.
RAS mutations appear across multiple tumor types.
Lung cancer.
Colorectal cancer.
Gynecologic cancers.
Other solid tumors.
Revolution Medicines is developing a portfolio of RAS(ON) inhibitors, including agents targeted more specifically at mutations such as G12C and G12D.
Daraxonrasib itself is also being studied in additional cancer settings and earlier lines of pancreatic cancer treatment.
But approval for pancreatic cancer does not mean doctors can assume the same survival benefit in other cancers.
Every tumor type requires appropriate clinical trials.
Cancer biology depends on much more than one mutation.
A drug that produces a dramatic result in pancreatic cancer may behave differently in colorectal or lung cancer even if both contain RAS abnormalities.
Could Rasonque Move Into First-Line Treatment?
This may become one of the biggest questions.
The current FDA indication is largely for patients who have already received systemic treatment.
But if the drug is effective after chemotherapy, researchers naturally want to know whether using it earlier could improve outcomes even further.
Revolution Medicines has already been studying daraxonrasib in first-line pancreatic cancer strategies, including combinations with other therapies.
That could eventually change treatment again.
A targeted RAS inhibitor might one day be combined with chemotherapy or another drug immediately after metastatic disease is diagnosed.
But those studies need to establish both safety and effectiveness.
For now, the approved indication remains the one supported by the evidence reviewed by the FDA.
The FDA Approved It More Than Six Months Early
The speed of the regulatory review attracted attention too.
The FDA approved Rasonque approximately 6.5 months ahead of its expected user-fee deadline, according to the agency.
The drug had received several expedited regulatory designations, including:
Breakthrough Therapy designation.
Orphan Drug designation.
Priority Review.
It was also reviewed through the FDA Commissioner’s National Priority Voucher pilot program.
Those programs are intended to accelerate review of treatments addressing serious diseases and major unmet medical needs.
The FDA had already allowed expanded access earlier in 2026 so eligible patients could receive daraxonrasib while formal review continued.
Cancer Centers Were Already Trying to Get the Drug
The excitement surrounding daraxonrasib began well before Wednesday’s approval.
Reuters reported in May that U.S. cancer centers were scrambling to enroll eligible patients in an expanded-access program after the Phase 3 survival results became known.
That is unusual.
Experimental drugs certainly generate interest, but oncologists generally remain cautious until strong randomized evidence appears.
Daraxonrasib’s survival results created a different level of urgency.
Patients with metastatic pancreatic cancer who had exhausted standard treatments could not necessarily wait months for the FDA review to finish.
The expanded-access program gave some patients an interim pathway.
Following approval, Revolution Medicines says patients participating in that program can transition toward commercially available therapy with their physicians.
How Much Will Rasonque Cost?
That remains one of the biggest unanswered questions.
As of the August 26 approval announcement, Revolution Medicines had not yet publicly disclosed final U.S. pricing and detailed commercial availability information, Reuters reported.
That will matter enormously.
Modern targeted cancer drugs can be extremely expensive.
Insurance coverage, copay assistance and manufacturer support programs can determine whether a scientifically successful treatment becomes practically accessible.
A medicine cannot transform pancreatic cancer outcomes if patients cannot obtain it.
Pricing and payer negotiations will therefore become the next major part of the story.
This Isn’t a Cure
The survival improvement is remarkable.
But language matters enormously when discussing a serious disease.
Rasonque does not cure metastatic pancreatic cancer.
The median patient in the trial eventually experienced disease progression.
Some patients did not respond.
Some experienced significant side effects.
And even the improved median overall survival remained measured in months rather than decades.
So describing the drug as a cure would be misleading.
A more accurate description is:
A major new therapy that substantially prolonged survival and delayed progression in a population with very limited treatment options.
That may sound less dramatic.
For patients with metastatic pancreatic cancer, it is still enormously meaningful.
It Also Doesn’t Mean Someone Should Stop Chemotherapy
Another possible misunderstanding is that Rasonque has made chemotherapy obsolete.
It has not.
The trial studied patients after previous treatment, and the FDA indication reflects that context.
Chemotherapy remains an important component of pancreatic cancer treatment.
For some patients it may still provide the best first-line approach.
Future studies may determine whether daraxonrasib works best alone, earlier in treatment or combined with other drugs.
Cancer treatment decisions depend on:
stage,
previous therapies,
tumor biology,
overall health,
organ function,
symptoms,
and individual patient goals.
Those decisions should be made with an oncology team rather than based on a headline about median survival.
The Biggest Breakthrough May Be Proving RAS Can Be Attacked Broadly
The immediate story is about pancreatic cancer.
The larger scientific story may be about RAS.
Cancer researchers spent decades staring at one of the most important oncogenic pathways while struggling to interfere with it.
Now a drug targeting active forms of RAS has produced a major survival advantage in a randomized Phase 3 pancreatic cancer trial and reached FDA approval.
That creates proof of principle.
If scientists can successfully drug RAS in pancreatic cancer, similar strategies may become useful across other RAS-driven tumors.
That does not guarantee success.
But it opens doors that once appeared permanently closed.
Why the “Double Survival” Headline Is Both Exciting and Easy to Misread
The headline is based on real numbers:
13.2 months versus 6.7 months.
That is close to twice the median survival.
But those numbers apply to a specific trial population.
Previously treated.
Metastatic.
Pancreatic adenocarcinoma.
Adults.
Patients eligible for the study.
It does not mean someone diagnosed tomorrow with a small surgically removable pancreatic tumor should expect the same result.
It does not mean everyone who takes Rasonque will gain exactly 6.5 months.
And it does not mean the drug eliminates pancreatic cancer.
Clinical medicine is more complicated than an average or median.
Still, the headline captures something real:
The improvement was unusually large.
Pancreatic Cancer Treatment Has Finally Gained a Major New Tool
Cancer medicine often advances slowly.
Three extra weeks.
A small reduction in recurrence.
A therapy that helps only 5% of patients.
Those improvements still matter, but they rarely transform expectations overnight.
Rasonque is different because of the magnitude of its late-stage trial result.
In previously treated metastatic pancreatic adenocarcinoma, median overall survival increased from 6.7 months with chemotherapy to 13.2 months with daraxonrasib, while disease progression was delayed and serious treatment-related side effects occurred less frequently than with chemotherapy.
That is why oncologists reacted so strongly when the data were presented earlier this year.
It does not solve pancreatic cancer.
It does something medicine had struggled to do for decades:
It directly attacks one of the molecular engines driving most pancreatic adenocarcinomas and produces a meaningful survival advantage.
For patients facing one of the deadliest common cancers, that is much more than another drug approval.
It is evidence that a cancer pathway once dismissed as “undruggable” may finally be giving up some of its defenses.
